Pioneering Phase 2 Imlifidase Study Reaches Enrollment Milestone in Fight Against Guillain-Barré Syndrome
Hansa Biopharma (Nasdaq Stockholm: HNSA), a leader in the development of innovative enzyme technology for rare immunological conditions, has successfully...